INTRODUCTION AND OBJECTIVES:
Percutaneous thermal ablation is a minimally invasive nephron-sparing treatment for RCC that provides an alternative to surgery for co-morbid patients. Most cryotherapy and RFA studies have focused on treatment of small RCC but treatment of larger tumors may be facilitated with high power microwave ablation (MWA). The purpose of this study is to compare oncologic outcomes for RCC patients with clinical T1b tumors following surgery or MWA.
METHODS: Comprehensive data was collected for consecutive RCC patients with cT1b tumors following treatment with MWA (NeuWave Medical), partial nephrectomy (PN) or radical nephrectomy (RN). Locally advanced or metastatic tumors were excluded. Patients were offered MWA after failing (growth >5mm/year) or refusing active surveillance. Univariate and multivariate Cox analysis evaluated associations between variables and survival outcomes.
RESULTS: A total of 326 patients (41 MWA, 74 PN and 211 RN) were identified between 2000-2017. Patients treated with MWA were older (p<0.001) and more comorbid (p<0.001) vs. surgery patients. No difference identified in gender, race, BMI, eGFR, and tumor diameter. Median follow-up was 41 months (IQR 14-81 months).
Local recurrence was identified in 3, 1, and 1 patients following MWA, PN, and RN. 5-year local recurrence free survival was lower following MWA (91.2%) vs. PN (97.9%) or RN (99.2%); p[0.001).
Three patients with local recurrence following MWA were treated with repeat ablation and had no evidence of residual disease after median of 29 months from the second ablation.
Progression Percutaneous cryoablation(PCA) is mentioned as only option for cT1 renal tumor because recurrence rate is relatively higher than that in partial nephrectomy. Salvage cryoablation can be performed for recurrent tumor, however its utility is unclear. We evaluated the utility and safety in patients treated with salvage cryoablation for recurrent tumor after primary PCA for cT1 renal tumor.
METHODS: We retrospectively analyzed the record of the patients who underwent PCA in our institution between November 2011 and March 2018. First, we analyzed overall survival(OS), cancer specific survival(CSS) and local recurrence free survival(L-RFS) in primary PCA using the Kaplan-Meier method and compared with log-rank tests. Second, we analyzed perioperative outcome and renal function and oncological outcome of salvage PCA compared with primary PCA.
RESULTS: A total 189 tumors underwent PCA (Primary: n [171, Salvage: n[18) . In Primary PCA group, 13 (7.6%) residues and 10 (5.8%) recurrences were later diagnosed. The median follow-up period was 26 months. The 3-year OS and CSS were 97.3% (95% CI:91.5-99.2) and 99.4% (95%CI:95.5-99.9) respectively. The 3-year L-RFS was 85. ). In multivariate analysis by cox proportional hazard model, age and high R.E.N.A.L score (>10) were independent prognostic factor for recurrence. In comparing Primary with Salvage PCA, perioperative overall complication rate had no significant difference in both groups. The 3-year L-RFS was no significant difference, Primary: 85.7% (78.0-90.9) vs. Salvage: 80.8% (41.0-95.0, P[0.854). Two patients in Salvage group had recurrence at 6 and 23 months respectively and underwent a third salvage PCA successfully. All tumors in Salvage group were able to be locally controlled.
CONCLUSIONS: Although PCA has higher local recurrence rate, local control can be obtained by salvage PCA. Salvage PCA after primary cryoablation failure is feasible, has a low complication rate, and acceptable mid-term oncologic outcomes. Further studies with durable follow-up are required.
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